Table 1. Frequencies and distributions of FGFR aberrations detected in our cohort.

Cancer type	N	Frequency of aberrations per cancer type (%)
		All	Distribution per gene						Distribution per mutation type
			FGFR1	FGFR2	FGFR3	FGFR4	Multiple FGFRs		Amp	Mutation	Fusion	Fusion + amp
Lung	8,922	6.19	3.49	0.67	1.33	0.18	0.52		3.08	2.71	0.36	0.03
Breast	750	14.27	10.8	2.53	0.13	0.27	0.53		11.07	2.0	0.13	1.07
Gastric	149	16.78	2.01	10.74	2.01	0	2.01		10.07	5.37	0	1.34
Colorectal	58	31.03	20.69	1.72	3.45	1.72	3.45		17.24	13.79	0	0
Soft tissue sarcoma	76	5.26	1.32	3.95	0	0	0		2.63	1.32	1.32	0
Ovarian	59	11.86	3.39	1.69	1.69	1.69	3.39		6.78	3.39	1.69	0
Esophageal	71	12.68	2.82	0	5.63	0	4.23		2.82	7.04	2.82	0
Pancreatic	87	4.60	2.3	1.15	0	1.15	0		2.3	2.3	0	0
Hepatobiliary	101	6.93	2.97	1.98	0	0	0		0.99	1.98	1.98	0
Melanoma	10	20	20	0	0	0	0		10	0	10	0
Endometrial	21	4.76	4.76	0	0	0	0		4.76	0	0	0
Cervical	16	12.5	0	0	12.5	0	0		0	0	12.5	0

Mutation refers to all non-amplification, non-fusion mutations including insertions or deletions, single base substitutions, multiple-nucleotide substitutions, and copy number deletion. N, screened population; amp, amplification.